Current treatments in diabetic macular oedema: systematic review and meta-analysis.

ABSTRACT: The aim of this systematic review is to appraise the evidence for the use of anti-VEGF drugs and steroids in diabetic macular oedema (DMO) as assessed by change in best corrected visual acuity (BCVA), central macular thickness and adverse events MEDLINE, EMBASE, Web of Science with Conference Proceedings and the Cochrane Library (inception to July 2012). Certain conference abstracts and drug regulatory web sites were also searched. Randomised controlled trials were used to assess clinical effectiveness and observational trials were used for safety. Trials which assessed triamcinolone, dexamethasone, fluocinolone, bevacizumab, ranibizumab, pegaptanib or aflibercept in patients with DMO were included. Risk of bias was assessed using the Cochrane risk of bias tool. Study results are narrative

SUBMITTER: Ford JA 

PROVIDER: S-EPMC3612765 | biostudies-literature | 2013 Mar

REPOSITORIES: biostudies-literature